New triple therapy tested for Tough-to-Treat liver cancer
NCT ID NCT06789757
Summary
This study is testing whether adding an oral medication called memantine to two standard cancer drugs (atezolizumab and bevacizumab) is more effective for treating advanced liver cancer that cannot be removed by surgery. It will enroll about 19 adults with newly diagnosed, untreated cancer to see if the three-drug combination shrinks tumors and improves quality of life. The treatment is given in 21-day cycles for six months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Inova Health Care Service
RECRUITINGFalls Church, Virginia, 22042, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Inova Schar Cancer Institute - Fair Oaks
RECRUITINGFairfax, Virginia, 22033, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.